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α and β asarones are natural constituents of some aromatic plants, especially species of
the genus Acorus (Araceae). In addition to reports of beneficial properties of asarones,
genotoxicity and carcinogenicity are also reported. Due to potential toxic effects of
β-asarone, a limit of exposure from herbal products of ∼2μg/kg body weight/day has
been set temporarily until a full benefit/risk assessment has been carried out by the
European Medicines Agency. Therefore, it is important to monitor levels of β-asarone in
herbal products. In this study, we developed a simple, rapid and validated GC-MS method
for quantitative determination of asarones and applied it in 20 pediatric herbal products
after detecting high concentrations of β-asarone in a product suspected to be implicated
in hepatotoxicity in a 3 month old infant. Furthermore, targeted toxicological effects
were further investigated in human hepatocytes (THLE-2 cells) by employing various in
vitro assays, with the goal of elucidating possible mechanisms for the observed toxicity.
Results showed that some of the products contained as much as 4–25 times greater
amounts of β-asarone than the recommended levels. In 4 of 10 samples found to contain
asarones, the presence of asarones could not be linked to the labeled ingredients, possibly
due to poor quality control. Cell-based investigations in THLE-2 cells confirmed the
cytotoxicity of β-asarone (IC50 = 40.0 ± 2.0μg/mL) which was associated with significant
lipid peroxidation and glutathione depletion. This observed cytotoxic effect is likely due to
induction of oxidative stress by asarones. Overall, the results of this study ascertained the
usability of this GC-MS method for the quantitative determination of asarones from herbal
products, and shed light on the importance of controlling the concentration of potentially
toxic asarones in herbal products to safeguard consumer safety, especially when the
target consumers are young children. Further investigations of the toxicity of asarones
are warranted.
Keywords: hepatotoxicity, drug induced liver injury, adverse events, herbal medicine, gas chromatography-mass
spectrometry, asarones
INTRODUCTION
α-asarone (1) and β-asarone (2), the cis-trans isomers (Figure 1)
are the natural constituents of some aromatic plants and
their essential oil fractions, especially species of the genus
Acorus (Araceae) including Acorus calamus, Acorus tatari-
nowii Schott and Acorus gramineus Soland (Commission of
Chinese Pharmacopoeia, 2005; European Medicines Agency,
2005). Acorus tatarinowii Schott is referred to as Acori tatari-
nowi Rhizoma or shi chang pu and consists of the dried rhi-
zome, cut in slices, of Acorus tatarinowii Schott (Commission
of Chinese Pharmacopoeia, 2005). Asarones are reported as
the major components of their essential oil (Commission of
Chinese Pharmacopoeia, 2005; European Medicines Agency,
2005). Asarones are reported to possess several beneficial
pharmacological properties (Lim et al., 2014; Meng et al., 2014;
Wang et al., 2014). Specifically, β-asarone is reported to cross
blood brain barrier and possesses beneficial effects on central
nervous system and cardiovascular system (Wu et al., 2005; Liu
et al., 2010; Meng et al., 2014). It has shown beneficial effects
in experimental models of diseases such as Alzheimer’s disease
(Geng et al., 2010; Li et al., 2010, 2012; Wei et al., 2013; Meng
et al., 2014), cerebral ischemia (Yang et al., 2013) and epilepsy
(Fu et al., 2008). Separately, α-asarone is reported to possess anti-
epileptic and hypolipidemic properties (Garduno et al., 1997;
Chen et al., 2013). The in vitro and in vivo neuroprotective effects
of α-asarone (Cho et al., 2002; Limón et al., 2009) and β-asarone
(Li et al., 2010; Zou et al., 2011; Nandakumar et al., 2013) have
also been reported. In addition, radioprotection and prevention
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FIGURE 1 | Chemical structures of α-asarone (1) and β-asarone (2).
of genotoxicity and hematopoetic injury by α-asarone is also
reported (Sandeep and Nair, 2011).
On the other hand, α-asarone and β-asarone are reported
to be genotoxic and hepatocarcinogenic in rodents. There are
also reports of their mammalian toxicity and carcinogenicity
(Hasheminejad and Caldwell, 1994; European Medicines Agency,
2005). It is reported that β-asarone is more toxic than α-asarone
(European Medicines Agency, 2005). In human studies, expo-
sure to asarones from the herb Acorus calamus, which contains
high concentrations of asarones, caused prolonged vomiting in
7 consumers (Björnstad et al., 2009). Cytotoxic and genotoxic
effects of asarones against HepG2 cells are also reported (Unger
and Melzig, 2012). The authors have demonstrated that after
metabolic activation, β-asarone at concentrations higher than
50μg/mL was genotoxic as indicated by positive Ames test and
sister chromatid exchange test (Unger and Melzig, 2012). Due
to potential toxic effects of asarone, in particular, β-asarone,
the European Council has limited the presence of β-asarone to
a maximum of 1mg/kg in alcoholic beverages and seasoning
for snack food and 0.1mg/kg in other food stuffs and bever-
ages (European Medicines Agency (EMEA), 2002). As an exten-
sion of the regulation (limitation of the intake of β-asarone
from food and alcoholic beverages), a limit of exposure from
herbal medicinal products of ∼115μg/day, i.e. about 2μg/kg
bw/day has been instituted temporarily until a full benefit/risk
assessment has been carried out (European Medicines Agency,
2005).
While genotoxicity and carcinogenicity of α and β-asarones
have been reported, hepatotoxic effects are not very well stud-
ied. Several reports and reviews on the involvement of herbal
medicine and herbal products in hepatotoxicity have been pub-
lished (MacGregor et al., 1989; Kaplowitz, 1997; Stedman, 2002;
Stickel et al., 2005; Navarro, 2009; Patel et al., 2012; Strader
et al., 2012; Abdualmjid and Sergi, 2013; Teschke et al., 2013;
Navarro and Lucena, 2014; Navarro et al., 2014). These reports
raise concerns on hepatotoxicity associated with herbal medicine,
and thereby draw our consideration for the effect of asarones
found in herbal products. One prior study has described the
cytotoxic effects of α and β-asarones in HepG2 cells (Unger
and Melzig, 2012). This isolated reported awaits further valida-
tion using independent models and for possible mechanisms of
their cytotoxic effects to be determined. Furthermore, HepG2
as a cancerous cell line may confound the interpretation of true
cytotoxicity with anti-cancer effects. Unlike normal hepatocytes,
it has limited drug metabolizing capacity and may not recapit-
ulate cytotoxicities arising from metabolites. Hence, alternative
cell models with competent P450 function such as THLE2 cells
may be needed (Pfeifer et al., 1993; Datta et al., 2007; Greene
et al., 2010; Saha et al., 2010a,b; Krajka-KuŸniak et al., 2012;
Zimmerman et al., 2012). López et al. (1993) studied effects of
micromolar concentrations of α-asarone on cultured rat hepa-
tocytes over 2 weeks. α -asarone was found to be hepatotoxic
by causing morphologic and ultrastructural alterations, triacyl-
glycerol accumulation (fatty liver), and inhibition of protein
synthesis and secretion in cultured rat hepatocytes. To the best
of our knowledge, there is no report of hepatotoxicity evaluation
of β-asarone in hepatocytes although it is more hepatocarcino-
genic and genotoxic compared to α-asarone (EuropeanMedicines
Agency, 2005). For this reason, β-asarone is the focus of this
investigation.
In view of the reported toxic effects of asarones, it is impor-
tant to develop analytical methods for their determination in
herbal products. Asarones have been studied previously by thin
layer chromatography (TLC), high performance liquid chro-
matography (HPLC), high performance thin layer chromatogra-
phy (HPTLC), gas chromatography-mass spectrometry (GC-MS)
and capillary electrophoresis methods (Oprean et al., 1998;
Hanson et al., 2005; Widmer et al., 2005; Chen et al., 2009;
Kumari et al., 2009; Meng et al., 2014; Wang et al., 2014). High
Performance Liquid Chromatograhpy tandem mass spectrom-
etry is also reported for analysis of β-asarone in rat plasma
(Nandakumar et al., 2013). Among these methods, GC-MS
is widely used for the analysis of asarones because of their
intrinsic volatility and specificity (Wang et al., 2014). However,
existing GC-MS methods require long analysis time (at least
18min) for the determination of asarones (Oprean et al., 1998;
Björnstad et al., 2009; Chen et al., 2009; Kumari et al., 2009;
Meng et al., 2014; Wang et al., 2014). Therefore, we aim to
develop an improved GC-MS method for rapid analysis of
asarones in herbal medicine and products derived from herbal
medicine.
The present study was conducted as a result of detection of
high concentration of β-asarone in a baby product (from one
batch) suspected to be implicated in drug induced liver injury
in Singapore. The hepatotoxicity was marked by worsening acute
liver failure in an infant. The objectives of this study were to per-
form hepatotoxicity assessment of potentially toxic asarones in
human hepatocytes and to develop a simple, reliable and rapid
GC-MS method for the quantitative determination of asarones in
herbal products.
MATERIALS AND METHODS
CHEMICALS AND REAGENTS
The analytical grade (ACS) ethanol and methanol were pur-
chased from the Tedia Company (Fairfield, OH, USA). The water
was treated with Milli-Q water purification system (Millipore,
Bedford, USA). Trichloroacetic acid (TCA), sodium dode-
cyl sulfate (SDS) malondialdehyde (MDA), diethyl maleate,
thiobaribituric acid (TBA), butylated hydroxytoluene (BHT),
sodium hydroxide (NaOH) and bovine serum albumin (BSA)
were obtained from Sigma-Aldrich (Singapore). Reference stan-
dards of α-asarone, trans-trimethoxycinnamic acid and eugenol
were obtained from Sigma-Aldrich (Singapore). β-asarone was
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obtained fromKarl-Roth (Germany). Authentic herb Acori tatari-
nowii Rhizoma was obtained from the National Institute for the
Control of Pharmaceutical and Biological Products (NICPBP),
China.
SAMPLES
Nineteen herbal products labeled for their use in children were
purchased from local herbal retail shops in Singapore. Product
20 was supplied by the Health Sciences Authority of Singapore
(HSA). One product, Product 20 from one batch, was suspected
to be implicated in drug induced liver injury marked by wors-
ening acute liver failure in a 3-month old infant in Singapore.
As the original patient sample of Product 20 was not enough to
perform necessary studies, same product from a different batch
was purchased. All of the above 20 products were not found to be
adulterated with any prescription drugs and did not exceed the
legal permissible limits of toxic heavy metals when analyzed by
in-house adulterant screening methods.
PREPARATION OF SAMPLES AND STANDARDS
Hundred microgram of product or powdered plant material was
extracted using 15mL of HPLC grade methanol by ultrasonica-
tion (230V, Branson model 5510, Danbury, CT, USA) for 15min.
The extracts were filtered and the final volume is adjusted to
15mL with methanol. One milliliter of this extract was then fil-
tered with a 0.45μm membrane filter for GC–MS analysis. Stock
solutions of α and β-asarone were prepared at the concentrations
of 1mg/mL respectively in HPLC grade methanol and stored at
24◦C in dark.Working solutions were diluted from the stock solu-
tions with methanol. A structurally similar compound, eugenol
was used as an internal standard. Stock solution of 1mg/mL
of internal standard was also prepared and stored in dark
at 24◦C.
GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS)
Agilent gas chromatography-mass spectrometry (Agilent 7980
GC-MS) instrument was used. A DB-5MS column of film thick-
ness 0.25μm, length 30.0m and diameter 0.25mm was used
with the carrier gas (helium) set at 1mL/min. The initial oven
temperature was set at 80◦C. It was then increased to 300◦C at
25◦C/min. The final temperature of 300◦C was held for 3.2min.
The total running time was 12min. The injection volume was
1μl using splitless mode. The data acquisition system was con-
trolled by MS ChemStation. The MS was operated in the electron
impact (EI) mode. MS data were recorded for 4.70–12min. Full
scan mass spectra were collected between 50 and 550 amu at 1.53
scan s−1. For SIM mode, ions with m/z of 208.1 were monitored
for the quantification of asarones. Ions with m/z of 193.1 and
165.1 were used as qualifier ions for asarones. For the internal
standard, eugenol,m/z 164.1 was monitored. The Wiley standard
chemical MS library, NIST library and spectra of reference stan-
dards were used in the identification when scan mode used for
analysis.
GC-MS METHOD VALIDATION
Themixed standard working solutions at each concentration were
injected in triplicate. The calibration curves were constructed by
plotting the ratio of peak areas of the asarone standards to the
peak area of internal standard against the corresponding concen-
tration. The LOD and LOQ of GC-MS method were determined
and calculated as the analyte concentrations with signal/noise
ratios of 3 and 10, respectively. Accuracy and precision of method
were determined by analyzing quality control (QC) samples at
three concentrations (low, mid and high), representing the entire
calibration range for α and β-asarone. The intra-day (n = 6)
and inter-day (n = 3) variations (intermediate precision) were
evaluated by three replicate measurements of the QC samples
in a single day and on three consecutive days, respectively. The
recoveries of asarones were determined by the standard addition
method.Mixed standard solutions of α and β-asarone at three dif-
ferent concentrations were added into a powder of A. tatarinowii
herb before extraction and were then analyzed in triplicate. The
unspiked sample solution was concurrently analyzed. Stability
of the stock solution after 1 week was evaluated by comparing
the determined concentrations of QC samples prepared from the
aged stock solution to that of freshly prepared stock solution.
Autosampler stability or post-preparative stability was also eval-
uated by re-injecting the processed QC samples (n = 3) kept at
24◦C for 48 h.
CELL CULTURE
THLE-2 cells purchased from the American Type Culture
Collection, ATCC (Manassas, VA, USA). They were grown in
LHC-9 medium (Life technologies, California, USA) in a flasks
pre-coated with collagen (2.9mg/mL), fibronectin (1mg/mL)
and bovine serum albumin (1mg/mL according to ATCC guide-
lines. ApoTox™ Triplex assay kit and GSH-Glo™ Glutathione
assay kit were obtained from Promega (Madison, Wisconsin,
USA).
MEASUREMENT OF CYTOTOXICITY
Cytotoxicity was evaluated using the WST-1 (Sodium 5-(2,
4-disulfophenyl)-2-(4-iodophenyl)-3-(4-nitrophenyl)-2H tetra-
zolium inner salt) assay (Roche, Germany) according to the
manufacturer’s instructions. THLE-2 cells were suspended at
optimum density (5 × 104 cells/mL) in LHC-9 medium sup-
plemented with 10% fetal bovine serum (FBS). 100μl of this
suspension was dispensed into 96- well plates. The cells were then
incubated for 24 h at 37◦C with 5% CO2. The medium was then
discarded from the wells. Hundred microliter of pure compo-
nents (up to 1.25mM) were then added to the wells separately.
The plates were then incubated for 72 h at 37◦C with 5% CO2.
The supernatant from all the wells was discarded. Then 100μl of
WST-1 solution (10% in media) was added into each well. The
plates were then incubated for 1.5 h at 37◦C with 5% CO2. After
incubation, the absorbance was measured at 440 nm. Cell viabil-
ity was expressed as a percentage of the control wells (n = 6).
The entire experiment was triplicated. The final results obtained
were expressed as a mean for three cell line passages and the
standard deviations (SD) were also calculated. Statistical analysis
was performed according to Student’s t-test by one way analy-
sis of variance. Significant difference was taken as p < 0.05. The
IC50 values were determined by Calcusyn 3.0 software (Biosoft,
Cambridge, UK). Each reported value was the mean ± SD from
the 3 independent experiments.
www.frontiersin.org February 2015 | Volume 6 | Article 25 | 3
Patel et al. Hepatotoxicity assessment of asarones
THIOBARBITURIC ACID REACTIVE SUBSTANCES (TBARS) ASSAY
TBARS assay was applied to estimate lipid peroxidation. THLE-
2 cells (2 × 105 cells/well) were seeded into pre-coated 6-well
plates. The cells were then incubated for 24 h at 37◦C with 5%
CO2. After 24 h of incubation at 37◦C with 5% CO2,the media
was discarded. Extracts of pure components and positive con-
trol (Diethyl maleate, 2.5mM) dissolved in DMSO were then
added at different concentrations (0–0.8mM). The plates were
then incubated for 24 h at 37◦C with 5% CO2. The media was
then discarded and the wells were washed with 500μl of phos-
phate buffer saline (PBS) twice. The cells were then harvested
for the preparation of cell lysate. Cells from 6-well plates were
scraped into a 1.5mL centrifuge tube containing 500μl of 2.5%
trichloroacetic acid (TCA) using cell scraper. The TCA solution
containing cells was then centrifuged at 13,000 rpm for 5min.
After centrifugation, the supernatant was collected for estima-
tion of malondialdehyde (MDA) formation and the cell pellets
were stored at −20◦C until analysis by Bradford assay for protein
estimation. To 80μl of cell lysate solution or appropriate MDA
standards in 96 well plates, 10μl of 1mM butylated hydroxy-
toluene (BHT) in ethanol, 50μl of 50% TCA in water and 75μl
of 1.3% TBA in 75mM NaOH were added. The plate was then
incubated for 45min at 60◦C and the reaction was stopped by
addition of 10μl of 20% SDS in water. The plate was then cen-
trifuged at 2000 rpm for 10min at 4◦C. The supernatant was
then transferred carefully to another micro plate and fluorescence
was measured (Ex: 485 nm/Em: 535 nm). Nanomoles of MDA
formed per mg of protein (determined using Bradford’s assay)
were then calculated using MDA standard calibration curve. For
Bradford’s assay, 2 mg/mL bovine serum albumin (BSA) solution
was diluted with 0.05 N NaOH to prepare a series of concentra-
tions in the range 0.125–1mg/mL to plot the calibration curve.
The cell pellets obtained from cell lysate were dissolved in 500μl
of 0.05N NaOH. 5μl of BSA standard, re-suspended protein pel-
lets or 0.05N NaOH blank is added to microtitre plate. 250μl
of Bradford 1× dye reagent was then added to above solution
in plate. The plate was then read at 595 nm after 15min of
incubation at room temperature. The protein concentration was
then determined from BSA standard calibration curve. Statistical
analysis was performed according to student’s t-test by one way
analysis of variance. Significant difference was taken as p < 0.05.
Each reported value was the mean ± SD from 3 independent
experiments.
GLUTATHIONE DEPLETION ASSAY
This assay was performed by using GSH-Glo™ Glutathione assay
kit from Promega (Madison, Wisconsin, USA). The kit con-
tain total Glutathione (GSH) lysis reagent, oxidized Glutathione
(GSSG) lysis reagent, luciferin generation reagent and glutathione
standard. THLE-2 cells (10 × 103 cells/well) were seeded into pre-
coated 96-well plates. The cells were then incubated for 24 h at
37◦Cwith 5%CO2. After 24 h,themediumwas discarded and two
sets of pure components dissolved in DMSO were then added at
different concentrations in serum free media (one set for reduced
glutathione (GSH) measurement and second set for oxidized glu-
tathione (GSSG) measurement). Appropriate concentrations of
glutathione standards were also added to wells without cells to
obtain the glutathione calibration curve. The plates were then
incubated for 72 h at 37◦C with 5% CO2. The medium was
then discarded from the wells and the cells were treated with
glutathione measurement kit in accordance to the manufac-
turer instructions. Briefly, after removal of media 50μl/well of
total Glutathione (GSH) lysis reagent or Oxidized Glutathione
(GSSG) lysis reagent, as appropriate for desired endpoint was
added. To the wells containing glutathione standards, 50μl/well
of total Glutathione (GSH) lysis reagent was added. The plate
was then shaken at room temperature for 5min. Then 50μl/well
of luciferin generation reagent was added to all wells. The plate
was then shaken briefly and incubated at room temperature
for 30min. After incubation, 100μl/well of luciferin detection
reagent was added. The plate was then shaken briefly and incu-
bated at room temperature 15min before measuring the lumi-
nescence using GloMax® Multi+ luminometer from Promega
(Wisconsin, USA). Calibration curves for GSH and GSSG were
then plotted (Note: Twomoles of GSH are generated per 1mole of
GSSG. Dividing the GSH concentrations by two gives the concen-
tration of GSSG). GSH and GSSG in THLE-2 cells after treatment
were then calculated and the ratio of GSH/GSSGwas calculated by
following formula: Ratio GSH/GSSG treated = [μM GSH–(μM
GSSG× 2)]/μMGSSG. Statistical analysis was performed accord-
ing to student’s t-test by one way analysis of variance. Significant
difference was taken as p < 0.05. Each reported value was the
mean ± SD from 3 independent experiments.
SIMULTANEOUS MEASUREMENT OF CELL VIABILITY AND
CASPASE-3/7 LEVELS
ApoTox™ Triplex assay kit from Promega was used for the simul-
taneous measurement of caspase-3/7 activation and cell viability
in the same sample well. The kit contains GF-AFC Substrate
(for cell viability), bis-AAF-R110 Substrate (for cytotoxicity)
and luminogenic DEVD-peptide substrate for caspase-3/7 and
Ultra-Glo™ Recombinant Thermostable Luciferase (to measure
caspase-3/7 activation). THLE-2 cells (10 × 103 cells/well) were
seeded into 96-well plates with white background. The cells were
then incubated for 24 h at 37◦C with 5% CO2. After incubation,
extracts and pure compounds were then added at different con-
centrations in media to the wells containing cells for two different
incubation periods (6 and 12 h). After incubation, 20μl each
of GF-AFC substrate (for cell viability) and bis-AAF-R110 sub-
strate (for cytotoxicity) reagent were added to all wells, and briefly
mixed by orbital shaking (300–500 rpm for ∼30 s). The plates
were then incubated at 37◦C for 30min. Then the fluorescence
was measured at excitation wavelength of 400 nm and emission
wavelength of 405 nm to measure cell viability. To the same plate,
100μl of Caspase-Glo® 3/7 reagent was added to all wells, and
briefly mixed by orbital shaking (300–500 rpm for ∼30 s). The
plates were then incubated for 30min at room temperature before
measuring luminescence (caspase activation, a hallmark of apop-
tosis). Average percentage cell viability and caspase-3/7 activation
for a well was expressed as a percentage of the control wells by
comparing the average fluorescence and luminescence of treated
wells against that of control wells in a triplicate manner. The
results obtained were expressed as a mean ± SD for three cell line
passages.
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RESULTS
METHOD DEVELOPMENT AND VALIDATION
Steam distillation and /or hydrodistillation are frequently used
methods for determination of β-asarone in plant materials
(Oprean et al., 1998; Kumari et al., 2009). However, such dis-
tillation methods require long extraction time and have more
processing steps. Ultrasonication is a very powerful and efficient
method for the extraction of plant material and does not involve
heat, which may degrade some of the thermally unstable prod-
ucts. Therefore, ultrasonication method was chosen instead of
other methods such as Soxhlet extraction, maceration and steam
distillation. Therefore, in this study, ultrasonication method was
optimized for the extraction of asarones from botanical health
products.
The GC-MS method was shortened from initial screening
method of 30min to 12min for rapid quantification of asarones.
This was achieved by optimizing temperature ramp to sepa-
rate α-asarone, β-asarone and the internal standard eugenol.
Although β and α-asarones are structural isomers, they were
well resolved at 6.3 and 6.6min respectively (Figure 2). Eugenol
eluted at 5.1min (Figure 2). Mass spectra of β-asarone, α-asarone
and eugenol were initially obtained by running in scan mode.
From these mass spectra, ions with m/z of 208.1 and 164.1 were
selected in SIM mode for asarones and eugenol respectively for
quantification. This GC-MS method has been validated. The lin-
earity data, concentration range, LOD and LOQ are presented in
Table 1. Absolute recovery or the extraction efficiency of asarones
(Table 2) was studied at three different concentrations from the
A. tatarinowii herb. Data of analytical recoveries of QC samples
for asarones and the stability of asarones at the tested conditions
are presented as supplementary materials (Tables S1, S2 respec-
tively). The calibration curves were found to have good linearity
(R2 > 0.999). The RSDs of intra- and inter-day precision for α
and β-asarones were 4.31–7.69 and 2.59–6.61 respectively. The
accuracy of the developed method was found to be satisfactory
as the percentage deviations of the QC samples from the nomi-
nal concentration were all within the acceptable limit of ± 10%
for the recovery of asarones. The absolute recoveries or extraction
FIGURE 2 | GC-MS chromatograms of Product 18. The internal standard eugenol, β-asarone and α-asarone were well separated at the retention time of 5.1,
6.3, and 6.6min respectively.
Table 1 | Linear regression data for the GC-MS method for quantification of asarones.
No. Asarone Calibration curve R2 Linear range (ng/mL) LOD (ng/mL) LOQ (ng/mL)
1 β-asarone y = 0.0014x + 0.1248 0.9993 156–5000 4.2 12.6
2 α-asarone y = 0.0016x + 0.2398 0.9997 156–5000 4.6 13.9
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Table 2 | Absolute recoveries or extraction efficiency of asarones from
the herb A. tatarinowii.
Asarone Concentration Mean recovery
of QC sample
(ng/mL) Intra-day (n = 6) Inter-day (n = 9)
% recovery % RSD % recovery % RSD
± SD ± SD
β-asarone 400 94.65±4.67 4.94 95.75±5.33 5.57
1000 92.84±5.89 6.34 93.79±7.21 7.69
4000 96.02±4.15 4.32 96.59±4.87 5.50
α-asarone 400 96.61±6.02 6.23 94.45±6.24 6.61
1000 91.46±3.15 3.44 90.61±2.35 2.59
4000 102.36±4.22 4.12 101.03±4.56 4.51
efficiency of asarones were all above 90%. The results of stability
studies under different conditions have shown that asarones were
stable at the tested storage and handling conditions.
QUANTIFICATION OF ASARONES IN HERBAL PRODUCTS
As discussed earlier, asarones are potentially toxic compounds
and therefore their concentrations in herbal medicinal products
particularly products used for infants and children who are more
prone to adverse events should be monitored. Hence, we con-
ducted a study to explore the prevalence of asarones in baby
products marketed in Singapore. Table 3 shows the analysis of
20 products for the presence of asarones. Of the 20 samples ana-
lyzed, α and β asarones were found to be present in 10 products
(50%). In six of 10 samples, the presence of asarone could be
attributed to the labeled ingredients. However, in four products,
the presence of asarones could not be explained by any of the
ingredients as labeled. This could be attributed to poor quality
control measure and/or mixing of herbs during manufacturing.
Subsequently, asarones were quantified in 10 products found to
contain asarones by the validated GC-MS method. In addition,
concentrations of asarones in the authentic herb Acori tatarinowii
were also estimated. The herb was found to contain 7679.8 ±
85.7mg/kg of β-asarone and 679.1± 20.3mg/kg of α-asarone. All
10 products were found to contain more than the recommended
amount of β-asarone as stipulated by EMEA (1mg/kg for alco-
holic beverages and 0.1mg/kg for other food stuffs). Particularly,
Product 20 was found to contain highest amount of β-asarone
from the 10 products. Table 4 also shows the estimated expo-
sure of β-asarones to the consumers of baby products that were
found to contain asarones. This estimation was based on the
average body weights of normal healthy consumers in Singapore
(Health Promotion Board, Singapore). The quantification and
estimation of exposure of asarones indicates that consumers are
likely to get exposed to the levels of β-asarones well above the
recommended exposure levels. Of the 10 products found to con-
tain β-asarone, 6 products were found to contain β-asarone more
than the daily recommended exposure levels. These products
were found to contain as much as 4–25 times more amount of
β-asarone than the recommended amount. These results sug-
gest that the β-asarone (in varied concentrations) is prevalent in
Table 3 | Screening and quantification of β-asarone and α asarone in
herbal products for children by GC-MS.
No. Name Concentration Concentration Source
of β-asarone of α-asarone
(mg/kg) (mg/kg)
1 Product 1 Not detected Not detected –
2 Product 2 Not detected Not detected –
3 Product 3 273.6 ± 21.6 40 ± 1.2 Acori tatarinowii
Rhizoma
4 Product 4 Not detected Not detected –
5 Product 5 230.9 ± 21.3 34.7 ± 1.2 Acori tatarinowii
Rhizoma
6 Product 6 4.8 ± 0.2 5.0 ± 0.2 Acori tatarinowii
Rhizoma
7 Product 7 11.2 ± 0.1 47.7 ± 3.0 Acori graminei
Rhizoma
8 Product 8 181.6 ± 5.4 106.1 ± 1.0 –
9 Product 9 Not detected Not detected –
10 Product 10 Not detected Not detected –
11 Product 11 181.6 ± 5.4 106.1 ± 1.0 unknown source
12 Product 12 4.3 ± 0.3 13.3 ± 0.1 unknown source
13 Product 13 3.2 ± 0.2 10.9 ± 3.3 Asari radix et
Rhizoma
14 Product 14 241.5 ± 10.5 53.2 ± 1.2 unknown source
15 Product 15 Not detected Not detected –
16 Product 16 Not detected Not detected –
17 Product 17 Not detected Not detected –
18 Product 18 243.5 ± 18.2 144.3 ± 7.1 unknown source
19 Product 19 Not detected Not detected –
20 Product 20 425.7 ± 28.2 62.8 ± 3.1 Acori tatarinowii
Rhizoma
21 Authentic herb
Acori tatarinowii
7679.8 ± 85.7 679.1 ± 20.3 Acori tatarinowii
Rhizoma
commercial herbal products available in the local market meant
for children and infants.
DETERMINATION OF CELL VIABILITY
The effects of asarones and extract of Product 20 on the cell
viability of human hepatocytes were evaluated using THLE-2
cells. Treatment of THLE-2 cells with varied concentrations of
α-asarone, β-asarone and extract of Product 20 for 72 h shows
that asarones and extract of Product 20 reduces cell viability
of hepatocytes in a dose dependent manner. The dose depen-
dent effects of asarones and Product 20 were further evaluated
to determine their IC50 values. The IC50values of α-asarone, β-
asarone and Product 20 were found to be 46.0 ± 1.0μg/mL
(0.221 ± 0.001mM), 40.0 ± 2.0μg/mL (0.193 ± 0.001mM), and
50.0 ± 0.8μg/mL respectively. We have further evaluated effects
of trans-trimethoxycinnamic acid, major metabolite of asarone
(Björnstad et al., 2009) on hepatocytes. Compared to α and β-
asarone, trans-trimethoxycinnamic acid was found to be very less
toxic. The IC50 value could not be determined as it did not kill
more than 50% cells even at highest concentration tested (i.e.,
IC50 > 350μg/mL).
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Table 4 | Estimation of daily exposure levels of β-asarone in herbal products for children.
Product Dose Daily exposure of
β-asarone based on
quantification
(μg/day)
Recommended
daily allowance as
per EMEA
guidelines (μg/day)
Product 3 Infants 6 months to 1 year: ½tsp; 1–3 years: 1 tsp; 3–6 years: 1–2 tsp; Adults: one
bottle each time. 3 times a day.
≤ 1 year: 172
1–3 years: 344
3–6 years: 344–688
Adults: 1067
≤ 1 year: 17–22
1–3 years: 22–27
3–6 years: 41
Adults: 115
Product 5 1–6 years: ½tsp flat; 7–12 years: 1 tsp flat; Adults:1/2 bottle. 3 times daily 1–6 years: 180
7–12 years: 360
Adults: 2880
1–6 years: 22–41
7–12 years: 41–72
Adults: 115
Product 6 1–6 years: ½tsp flat; 7–12 years: 1 tsp flat; Adults:1/2 bottle. 3 times daily 1–6 years: 4
7–12 years: 8
Adults: 58
1–6 years: 22–41
7–12 years: 41–72
Adults: 115
Product 7 1–3 years: 1 tsp each time; 3–6 years:1 or 2 tsp each time; Adults:1 bottle each time,
3 times a day
1–3 years: 21
3–6 years: 21–42
Adults: 84
1–3 years: 22–27
3–6 years: 41
Adults: 115
Product 11 1–5 years: 1 tsp each time; 5 year or more; 1–2 tsp each time. 4 times a day 1–5 years: 370
≥ 5 years: ≥ 370
1–5 years: 22–41
≥5 years: 41–115
Product 12 1–3 years: 400mg each time; adults: 650mg (1 bottle) each time. 2–3 times a day 1–3 years: 3.5
Adults: 5.6–8.4
1–3 years: 22–27
Adults: 115
Product 13 One bottle each time, 2 times daily; infant mth old ½bottle each time, 2 times a day Infants: 6.4
Adults: 12.8
Infants: 14
Adults: 115
Product 14 3 months-1 year: ½bottles each time; children 1–5 years old: 1 bottle each time;
Children 5 years old and above: 1–2 bottles each time, 4 times a day.
≤ 1 year: 193
1–5 years: 386
>5 years: 386–773
≤ 1 yr: 14–22
1–5 years: 22–41
>5 years: 52–115
Product 18 1–5 years: 1 tsp each time; 5 years and above: 1–2 tsp each time. Four times a day. 1–5 years: 623
>5 years: >623
1–5 years: 22–41
>5 years: 52–115
Product 20 1–3 years: one tube per day; 4–10 years: 2 tubes per day. 1–3 years: 128
4–10 years: 255
1–3 years: 22–41
4–10 years: 41–72
TBARS ASSAY TO MEASURE LIPID PEROXIDATION
Determination of lipid peroxidation was performed using THLE-
2 cells after 24 h of incubation using TBARS assay. Lipid per-
oxidation is quantified by measuring malondialdehyde (MDA),
a breakdown product formed from polyunsaturated fatty acids
(PUFA) hydroperoxides. Effects of asarones and extract of
Product 20 on formation of MDA were determined at three dif-
ferent concentrations. The levels of MDA were increased with
increasing concentration of asarones from 0.3 to 0.8mM, as com-
pared to vehicle control (Figure 3). The methanol extract of
Product 20 was also found to have significant lipid peroxida-
tion inducing effects at 0.2mg/mL concentration. The asarones
were also found to have cause similar level of lipid peroxidation
as that of positive control diethyl maleate (2.5mM) at 0.8mM
concentration.
GLUTATHIONE DEPLETION ASSAY
Ratio of reduced glutathione (GSH) and oxidized glutathione
(GSSG) was measured in THLE-2 cells after 72 h of incubation
after treatment with asarones and Product 20. Increased lev-
els of oxidized form of glutathione (formed as results of ROS
scavenging) are indicative of oxidative stress. As can be seen
from Figure 4, asarones produced significant glutathione deple-
tion as evident by the increased formation of GSSG particularly
at the concentration of 0.75mM compared to vehicle control.
Similarly, methanol extract of Product 20 also depleted GSH levels
at 0.15mg/mL concentration.
SIMULTANEOUS MEASUREMENT OF CELL VIABILITY AND
CASPASE-3/7 LEVELS
Effects of α and β-asarone on caspase-3/7 levels were deter-
mined after incubating THLE-2 cells for 6 and 12 h. THLE-2
cells were exposed to four different concentrations of asarones
to evaluate the dose dependent effects of asarones in casapse-3/7
levels. Increased levels of caspase-3/7 accompanied by reduced
cell viability were observed upon treatment with asarones at
both timepoints as compared to control cells not receiving treat-
ment (Figure 5). This implies that α-asarone and β-asarone could
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FIGURE 3 | The plot shows the average nanomoles of MDA
permg of protein ± standard deviation of three independent
experiments upon treatment with methanol extracts of Product
20, α and β-asarones against THLE-2 cells for 24h. Significant
difference (∗) was taken as p < 0.05 in comparison with untreated
control cells.
FIGURE 4 | The plot shows the ratio of GSH (reduced
form)/GSSG (oxidized form) (mean ± SD, n = 3) upon
treatment with methanol extracts of Product 20, compounds α
and β-asarones against THLE-2 cells for 72h. Significant
difference (∗) was taken as p < 0.05 in comparison with untreated
control cells.
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FIGURE 5 | Effects on caspase-3/7 activation and cell viability
after treatment with (A) β-asarone for 6 h, (B) β-asarone for
12h, (C) α-asarone for 6h and (D) α-asarone for 12h. The plot
represents average % caspase-3/7 levels on primary Y-axis and %
cell viability on secondary Y-axis ± standard deviation at different
concentrations.
cause cell death by apoptosis as evident by increased levels of
caspase-3/7. Compared to β-asarone, the α-asarone was more
potent in inducing caspase-3/7 levels. After 12 h of incubation
with α-asarone, the levels of caspase-3/7 were 600% more than
that of control cells.
DISCUSSION
Compared to the extensive investigations of hepatotoxicity due to
prescription drugs, much less is known about the safety of herbal
products (Willett et al., 2004). In some cases, hepatotoxicity has
been related to the presence of undeclared prescription drugs
and/or their synthetic analogs and ingestion of botanicals con-
taining known hepatotoxins (e.g., pyrrolizidine alkaloids). Several
reports of involvement of herbal products in drug-induced liver
injury raise concerns on the safety of herbal products (Stickel
et al., 2005; Navarro, 2009; Teschke et al., 2013). In our previous
study involving analyses of adverse events reports associated with
the use of herbal products in the Singapore Pharmacovigilance
database over a 12 years period, we found that the liver was the
major organ involved in serious adverse events (Patel et al., 2012).
Hepatotoxicity associated with the use of herbal products and
health supplements was responsible for 10 deaths in Singapore
in the period 1998–2009 (Patel et al., 2012). There were 15 cases
of hepatic failure in Singapore during 1998–2009. In one of those
15 cases, an herbal product (Product 20) from one batch was sus-
pected to be implicated to cause acute liver failure in 3-month
old baby. The suspected product was not found to be adulter-
ated with any prescription drugs during routine screening in
our laboratory and also by Health Sciences Authority, Singapore.
However, high concentrations of β-asarone were detected in
this product. Although asarones are potentially genotoxic and
carcinogenic, their hepatotoxic effects have not been ascertained.
Considering their detection in herbal products in children, and
their potential toxic effects, it is important to estimate their pres-
ence in such products as well as to evaluate their hepatotoxic
potential.
To achieve this, we developed and validated GC-MS method
for the quantitative determination of asarones in herbal products.
The advantage of our method is the short run-time of 12min
for simultaneous determination of asarones compared to previ-
ously reported GC-MS methods where minimum analysis time is
18min. The developed method was successfully applied to screen
for the presence of asarones in 20 herbal products. Some of the
products were found to contain greater amounts of β-asarone
than the recommended levels. In six out of ten products found to s
contain asarones, the presence could be attributed to the presence
of herbs containing asarones such as Acori tatarinowii Rhizoma,
Acori graminei and Asari radix et Rhizoma. In the remaining four
samples found to contain asarones, the presence of asarones could
not be linked to the labeled ingredients. Herbs Acori tatarinowii
Rhizoma, Acori graminei and Asari radix et Rhizoma belong to
the same genus as A. calamus, a herb prohibited from use in any
medicinal or food preparations in US The Electronic Code of
Federal Regulations (e-CFR)1. To investigate the abundance of
asarones in Acori tatarinowii, we have also quantified the con-
centration of β-asarone in this herb. According to the Chinese
Pharmacopoeia, the recommended dose of this herb is 3–9 g
1The Electronic Code of Federal Regulations (e-CFR), Title 21, Chapter I,
Subchapter B, Part 189, Available online at: http://www.ecfr.gov/cgi-bin/text-
idx?c=ecfr&rgn=div5&view=text&node=21:3.0.1.1.16&idno=21#se21.3.189_
1110 (Accessed November 12, 2014).
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(Chen et al., 2009). Based on such recommended dose in Chinese
Pharmacopoeia and determined concentration in this study, the
β-asarone exposure levels would be 23,000–69,000μg, which is
extremely higher than the recommended levels. The biological
exposure and clinical significance are of course also highly depen-
dent on the processing of the herb, bioavailability and intrinsic
toxicity (if any) of the components. The limit of exposure from
herbal medicinal products has been set at 115μg β-asarone/day.
To meet recommended exposure levels, the amount of this herb
should not exceed 15mg in daily dose of herbal products to ensure
safe usage of this herb. This means that stricter quality control
measures and regulatory actions would be required to monitor
such a small amount of this herb in botanical health products.
Unlike A. calamus, this herb is not controlled by any regulatory
authorities for its concentration in herbal preparations and no
limits have been set up except for Health Canada. The Canadian
regulations do not allow this herb in food without prior licens-
ing because of its potential health risks (Health Canada)2. The
results of this study indicate a need to conduct detailed evalua-
tion of this herb to consider its regulation in herbal preparations.
Similarly, assuming the daily intake of the herbal drug to be 3 g
for adults (Chen et al., 2009), the content of β-asarone per gram
of herbal product should not exceed 38μg per daily dose (Chen
et al., 2009). If we apply this limit to the 10 products which were
found to contain β-asarone, 8 of the products would exceed this
limit. The results of this study highlight the importance of mon-
itoring the levels of β-asarone in herbal products. Similar study
involving determination of asarones content in herbal products
for adults also reported high concentrations of asarones, espe-
cially for β-asarone (Zuba and Byearska, 2012). Herbal products
in the form of pellets and tablets were seized by the police due
to the intoxication of a young woman. Similar to our study, the
concentrations of asarones in most of the examined pellets and
tablets exceeded the maximum acceptable daily intake (Zuba and
Byearska, 2012).
Chen et al. (2009), proposed extraction method involving
preparation of decoction by heating to reduce the concentration
of β-asarone in the A, tatarinowii extract. Their results indi-
cated that by heating for 1 h, the concentration of β-asarone
was reduced by 85%. However, even after this reduction, the
β-asarone content was still very high (Chen et al., 2009). They
proposed that extended heating for 1–3 h is required to achieve
acceptable β-asarone levels. However, it is an unfavorable pro-
cess for herbal preparations in practice. Moreover, in multi-
component botanical health products, when this herb is added
in powder form, the proposed extended heating method is not
feasible. Therefore, further studies are required to derive practi-
cal and acceptable method of processing of this herb if it has to
be used. Moreover, the product suspected to cause hepatotoxicity
(Product 20) was not meant for its usage in infants even though
it was given to the baby by parents. This suggests that there is a
need to improve awareness amongst the consumer for correct use
of botanical health products. Furthermore, label warnings such
2Natural Health Products Ingredients Database. Available online
at: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredReq.do?id=13339&lang=
eng (Accessed February 13, 2015).
as “not for children’s below one year” could also help to prevent
such life-threatening adverse events. In addition, this study shows
the importance of consulting a qualified practitioner before con-
suming any herbal products to avoid potential unwanted effects
of herbal products. To the best of our knowledge, this is the
first report of determination of asarones in herbal products for
children.
To associate the observed high concentrations of asarones
in the suspected product and other products purchased from
the local herbal shops to their potential hepatotoxicity, we per-
formed hepatotoxicity evaluation of asarones through various
in vitro assays using immortalized human hepatocytes (THLE-2
cells) and investigated the possible mechanisms involved for the
observed effects in hepatocytes. These immortalized human liver
cells were selected for their metabolic competency and stability as
an in vitromodel for pharmacotoxicological studies (Pfeifer et al.,
1993). THLE-2 cells are able to metabolize benzo[a]pyrene, N-
nitrosodimethylamine, and aflatoxin B1 to their metabolites that
adduct DNA, causing cancer. This indicates functionality similar
to human liver (Pfeifer et al., 1993). THLE-2 cells have been used
to study the hepatotoxicity of oral hypoglycaemic agents such as
triglitazone (Saha et al., 2010a). Saha et al. (2010b) also reported
that THLE-2 cells were able to metabolize triglitazone into its
reactive metabolites. Furthermore, THLE-2 cells are also reported
to be used at Pfizer, Astra Zeneca and Bristol-Mayer-Squibb for
the screening of hepatotoxic potential of drug candidates (Greene
et al., 2010; Thompson et al., 2011). In addition, THLE assay
can also be used as a high throughput assay to prioritize com-
pound selection for in vivo toxicity screening (Greene et al.,
2010).THLE-2 cells have also been used as control cells represent-
ing normal human liver cells (Mayoral et al., 2005; Datta et al.,
2007; Krajka-KuŸniak et al., 2012; Zimmerman et al., 2012).
The IC50 values obtained from the cell viability assay indicate
that asarones and the methanol extract of Product 20 are cyto-
toxic to hepatocytes. Although β-asarone was found to be slightly
more cytotoxic than α-asarone, the difference was not statistically
significant. Pharmacokinetic study of β-asarone by Fang et al.
(2012) to study the transformation and excretion of β-asarone in
rabbits has shown that about 22% of β-asarone is converted to α-
asarone in rabbits. Previous studies conducted on rat hepatocytes
have identified trans-trimethoxycinnamic acid (trans-TMC) as
the major metabolite of α-asarone. Trans-TMC was also iden-
tified as metabolites of asarones in C. elegans, microbial model
for mammalian drug metabolism (Björnstad et al., 2009). In
contrast, in humans, cis-TMC and hydroxylated β-asarone were
identified as major metabolites of asarones in an analysis of urine
samples of patients with A. calamus oil intoxications in Sweden
(Björnstad et al., 2009). As trans-TMC is commercially available,
further experiments were conducted to determine the toxicity of
trans-TMC in hepatocytes. However, trans-TMC was found to
be five times less toxic than the β-asarone. Therefore, the trans-
TMC does not seem to be the toxic metabolite of asarones. Our
results and the study by Björnstad et al. (2009) suggests that
metabolites other than trans-TMC, such as cis- TMC could be
involved in the toxicity of asarones. Cis-TMC is not commer-
cially available and its toxicity could not be assessed in the present
study.
Frontiers in Pharmacology | Ethnopharmacology February 2015 | Volume 6 | Article 25 | 10
Patel et al. Hepatotoxicity assessment of asarones
To investigate possible mechanisms of the cytotoxicity in hep-
atocytes, we determine lipid peroxidation and glutathione deple-
tion in THLE-2 cells after treatment with asarones, as biochemical
indicators of oxidative stress (Tripathi et al., 2009). Elevation of
ROS in hepatocytes is reported to be one of the main mechanisms
for drug induced hepatotoxicity. This ROS induced hepatic cell
toxicity leads to a variety of manifestations of liver diseases such as
ischemia–reperfusion injury, fibrosis and liver failure (Novo and
Parola, 2008). These outcomes arise from damaging effect of ROS
on various subcellular components. For example, these radicals
cause peroxidation of the cell membrane phospholipids which
results in accumulation of lipid peroxides leading to the disrup-
tion of membrane structure and function. ROS also affects the
anti-oxidant defense system involving glutathione. Glutathione
(GSH) is an abundant antioxidant, which protects cells from ROS
such as free radicals and peroxides (Griffith, 1999; Sies, 1999)
through sacrificial oxidation to its oxidized form glutathione
disulfide (GSSG) during oxidative stress. In healthy cells and
tissue, more than 90% of the total glutathione pool is in the
reduced form (GSH) and less than 10% exists in the oxidized form
(GSSG). A reduced ratio of GSH to GSSG within cells is used as
an indicator of oxidative stress and cellular toxicity (Ghezzi, 2005;
Ballatori et al., 2009). The depletion of total GSH also suggests
adduct formation with reactive metabolites (in the form of GSH
conjugates).
From lipid peroxidation assay, α and β-asarones and Product
20 were found to cause oxidative stress in a dose-dependent man-
ner as indicated by the increased formation of MDA. Similar
observations were made with glutathione depletion assay. This
data suggests that pure asarones and products containing high
concentrations of asarones are producing cellular damage in
hepatocytes by oxidative stress. While the exact chemical entity
responsible for the damage is not directly investigated, previous
studies pointed at the formation of reactive metabolites which are
capable of generating ROS. Hasheminejad and Caldwell (1994)
reported that genotoxicity of asarones could be due to their
oxidized metabolites such as trans-2, 4, 5-trimethoxycinnamic
acid which is the product of ω-oxidation. Their conclusion was
based on the observation that the CYP-450 inhibitor, cimetidine,
was able to block the genotoxicity of asarones (Hasheminejad
and Caldwell, 1994). However, trans-2, 4, 5-trimethoxycinnamic
acid exhibited little toxicity in our cell model as compared to
the parental asarones. Other reactive metabolites could arise
from epoxidation of carbon-carbon double bond of asarones
(Hasheminejad and Caldwell, 1994). Moreover, the w-oxidation
and subsequent sulfation of asarones could also lead to formation
of reactive carbonium ions (Tsai et al., 1994). Therefore, further
work is required to characterize the metabolites responsible for
the observed toxicity of asarones.
After investigating the oxidative stress inducing effects of
asarones in hepatocytes, we characterized the mode of cell death
that ensued this injury. Apoptosis is usually manifested by activa-
tion of specific proteases such as caspase-3 and 7. α-asarone and
β-asarone were found to induce caspase-3/7 activation implying
cell death by apoptosis. These results corroborated earlier works
where β-asarone directly induced apoptosis in LoVo colon can-
cer cells by up-regulation of caspases through a mitochondrial
pathway in vitro and in vivo (Zou et al., 2012). However, β-asarone
is also reported to reduce apoptosis by inhibiting caspase-3 activa-
tion (Li et al., 2010; Liu et al., 2012). However, direct comparison
cannot be made as their study involved investigations of the
effect of β-asarone after deliberately inducing apoptosis by use
of neurotoxin and also there are differences in cellular system
used. This comparison further accentuates the importance of
using tissue-specific system to derive mechanistic information of
relevance to clinical observations, such as in herb-mediated hep-
atotoxicity. To the best of our knowledge, this is the first report of
the effects of asarones on human liver cells. The presence of high
concentration of potentially toxic asarones in herbal products and
their unsupervised consumption especially in infants and young
children who are more prone to hepatotoxicity sets the impetus
to understand more about the role of asarones in in vivo drug
induced liver injury.
CONCLUSION
In this study, a simple, rapid and validated GC-MS method
for quantitative determination of asarones in herbal products
is developed and applied for the analysis of herbal products
used in children including a product suspected to be implicated
in hepatotoxicity. In addition, asarones were also evaluated for
their hepatotoxic effects using human hepatocytes and possible
mechanisms of their observed effects were also studied. High con-
centrations of asarones were found in some of the tested products.
Asarones were also found to exhibit cytotoxicity to hepatocytes
possibly by inducing oxidative stress. The results of this study
shed light on the importance of controlling the concentration of
potentially toxic asarones in herbal products to safeguard con-
sumer safety especially young children. Further investigations of
the toxicity of asarones are warranted.
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